Aerie Completes Enrollment of Phase 3 Glaucoma Study in Japan
17 June 2021 - 9:10PM
Dow Jones News
By Matt Grossman
Aerie Pharmaceuticals Inc. has completed patient enrollment of a
Phase 3 study in Japan testing its netarsudil ophthalmic solution
as a treatment for glaucoma or ocular hypertension, Aerie said
Thursday.
The Durham, N.C.-based pharmaceutical company said that the
study has enrolled 245 patients. The patients have received
treatment either with netarsudil or with ripasudil, another
solution that is approved in Japan. The trial is expected to be
completed by the end of 2021, Aerie said.
Netarsudil has already been approved to treat some eye
conditions in the U.S. The Japanese study is being co-funded with
Santen Pharmaceutical Co., which has an exclusive collaboration and
license agreement with Aerie for netarsudil in Japan and other
Asian countries.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
June 17, 2021 06:55 ET (10:55 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Santen Pharmaceutical (PK) (USOTC:SNPHY)
Historical Stock Chart
From Nov 2024 to Dec 2024
Santen Pharmaceutical (PK) (USOTC:SNPHY)
Historical Stock Chart
From Dec 2023 to Dec 2024
Real-Time news about Santen Pharmaceutical Company (PK) (OTCMarkets): 0 recent articles
More Santen Pharmaceutical Company (PK) News Articles